Simris Alg AB Class B (SIMRIS.B) AI Stock Analysis

• Market Cap: kr55.41M
• Dividend Yield: N/A
• Average Volume (3M): 223.88K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: -49.72%
• EPS Growth: 36.20%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 842,104,900
• 10 Day Avg. Volume: 120,731
• 30 Day Avg. Volume: 223,875
• PEG Ratio: 0.02
• Price to Book (P/B): 4.70
• Price to Sales (P/S): 9.18
• P/FCF Ratio: -1.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: kr0.06 ▲(55.00% Upside)

The score is primarily held down by very weak financial performance—declining revenue, extremely negative margins, ongoing cash burn, and a thin equity base that raises solvency risk. Technical indicators are mixed with only short-term improvement against a broader downtrend, and valuation is difficult to justify due to losses (negative P/E) with no dividend yield support.

Positive Factors

Gross Margin

A 42.11% gross margin indicates the core algae-oil product has strong unit economics. That level of product margin provides a structural foundation to move toward profitability if fixed costs are reduced or volumes scale, supporting longer-term margin improvement.

Debt-Free Capital Structure

Having no reported debt materially lowers fixed financial obligations and interest risk, giving management structural flexibility to prioritize operations or raise equity. This reduces insolvency pressure during cash burn and supports strategic options over the medium term.

Vertically Integrated Algae Platform

Control across cultivation, processing and commercialization creates durable advantages: quality control, supply security, and potential cost capture. Vertical integration supports differentiated products and long-term positioning in sustainable omega-3 and specialty ingredient markets.

Negative Factors

Declining Revenue

A nearly 50% revenue drop undermines scale economics and limits ability to absorb fixed costs. Sustained top-line decline reduces the pathway to profitability, weakens bargaining power with customers/suppliers, and increases reliance on external funding to sustain operations.

Deep Negative Profitability

An extreme negative EBIT margin signals structural unprofitability where operating losses far exceed revenues. Without significant cost restructuring or meaningful revenue recovery, such deep losses erode shareholder equity and make long-term viability dependent on repeated capital injections.

Cash Burn and Weak Solvency

Sustained negative operating cash flow combined with a very low equity ratio creates structural solvency risk. The company will likely need continual external financing, increasing dilution risk and constraining investments in growth or commercialization over the medium term.

Simris Alg AB Class B Business Overview & Revenue Model

Company Description

Simris Alg AB Class B (SIMRIS.B) is a Swedish biotechnology company focused on the sustainable production of high-value products derived from microalgae. Operating primarily in the sectors of food, health, and nutrition, Simris Alg specializes in cultivating various species of algae to create ingredients such as omega-3 fatty acids, proteins, and other bioactive compounds. The company aims to provide natural alternatives to commercially available products, promoting health and wellness while minimizing environmental impact.

How the Company Makes Money

Simris Alg generates revenue primarily through the sale of its algae-derived products, which include omega-3 supplements and other nutritional ingredients. The company has developed a range of branded products aimed at both consumers and health-focused businesses. Key revenue streams include direct sales to consumers via e-commerce platforms, partnerships with health and wellness retailers, and collaborations with food and supplement manufacturers seeking natural ingredients. Additionally, strategic partnerships with research institutions and collaborations with other companies in the biotechnology space enhance its R&D capabilities and market reach, contributing positively to its financial performance.

Simris Alg AB Class B Financial Statement Overview

Summary

Weak fundamentals: revenue declined (SEK 4.35M in 2023 to SEK 2.89M in 2024), profitability is deeply negative (2024 EBIT margin -1201%), cash flow remains negative (operating cash flow SEK -18.02M), and the balance sheet shows low equity with a very low equity ratio (3.59%), increasing solvency risk.

Income Statement

Simris Alg AB Class B has faced declining revenues, evident from a revenue drop from SEK 4.35M in 2023 to SEK 2.89M in 2024. Consistent negative EBIT and EBITDA margins highlight operational inefficiencies, with the EBIT margin at -1201% for 2024. Despite a gross profit margin of 42.11% in 2024, the net profit margin remains deeply negative, reflecting significant net losses. These factors indicate substantial challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a highly leveraged position with a debt-to-equity ratio at zero due to no reported debt, but low equity levels of SEK 5.64M. The equity ratio has drastically decreased to 3.59% in 2024, suggesting potential solvency issues. The return on equity is negative due to persistent net losses, which raises concerns about shareholder value.

Cash Flow

Operating cash flow improved compared to the prior year, though still negative at SEK -18.02M in 2024, indicating ongoing cash burn. The free cash flow remains negative, suggesting unsustainable operations without external financing. Despite this, financing cash flow at SEK 14.91M shows efforts to secure additional funding. The free cash flow to net income ratio remains negative, reflecting challenges in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.58M	2.89M	4.35M	4.08M	6.14M	2.17M
Gross Profit	1.80M	1.22M	2.01M	-742.00K	-2.07M	-2.75M
EBITDA	-12.86M	-17.59M	-22.36M	-18.00M	-24.81M	-20.66M
Net Income	-29.35M	-34.60M	-37.30M	-24.42M	-28.36M	-25.60M
Balance Sheet
Total Assets	144.79M	157.06M	174.55M	185.71M	29.20M	57.06M
Cash, Cash Equivalents and Short-Term Investments	1.03M	1.95M	5.67M	3.99M	961.00K	16.51M
Total Debt	90.78M	2.04M	2.67M	2.13M	3.13M	3.99M
Total Liabilities	152.53M	151.42M	148.94M	162.68M	10.98M	9.64M
Stockholders Equity	-7.75M	5.64M	25.61M	23.03M	18.22M	47.42M
Cash Flow
Free Cash Flow	-13.32M	-18.63M	-37.96M	-40.57M	-18.39M	-19.77M
Operating Cash Flow	-13.32M	-18.02M	-36.35M	-18.19M	-18.14M	-19.48M
Investing Cash Flow	-613.00K	-613.00K	-1.61M	-22.38M	-253.00K	-286.00K
Financing Cash Flow	13.22M	14.91M	39.63M	43.60M	2.84M	28.42M

Simris Alg AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.07, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.16 is Neutral, neither overbought nor oversold. The STOCH value of 62.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SIMRIS.B.

Simris Alg AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXPRS2	46 Neutral	kr51.97M	-0.79	-88.65%	―	8.46%	11.73%
PILA	45 Neutral	kr54.20M	-3.11	-601.02%	―	―	―
MODTX	43 Neutral	kr37.70M	-1.37	-166.94%	―	―	-19.35%
SIMRIS.B	41 Neutral	kr55.41M	-1.13	―	―	-49.72%	36.20%
ONCOZ	41 Neutral	kr65.64M	-8.13	-78.79%	―	―	20.55%
LPGO	41 Neutral	kr7.27M	-0.08	-213.85%	―	―	―